Healthcare Providers and Services
Company Overview of Dana-Farber Cancer Institute, Inc.
Dana-Farber Cancer Institute, Inc. provides cancer treatment and research services for adults and children in the United States. It offers adult treatment and care services for blood, breast, cutaneous/skin, gastrointestinal, genitourinary, gynecological, head and neck, hematology, melanoma, neuro-oncology, sarcoma, and thoracic cancer; and cancer genetics and prevention services. The company also provides treatment and care for children with cancer, such as blood diseases, bone and soft tissue tumors, brain tumors, histiocytosis, Hodgkin lymphoma, kidney tumors, leukemia, neuroblastoma, non-Hodgkin lymphoma, and rare tumors program. In addition, it offers training in cancer treatment and re...
450 Brookline Avenue
Boston, MA 02215-5450
Founded in 1947
Key Executives for Dana-Farber Cancer Institute, Inc.
Chief Executive Officer and President
Chief Financial Officer and Assistant Treasurer
Chief Operating Officer and Executive Vice President
Senior Vice President and General Counsel
Compensation as of Fiscal Year 2015.
Dana-Farber Cancer Institute, Inc. Key Developments
Eli Lilly and Company and Dana-Farber Cancer Institute Announce Research Collaboration
Jun 17 15
Eli Lilly and Company and Dana-Farber Cancer Institute announced a multiyear collaboration to research new medicines under development to fight cancer. As per the agreement, over the course of three years Dana-Farber will provide research and development expertise for a number of early-stage Lilly oncology compounds. Dana-Farber researchers and Lilly scientists will work collaboratively on preclinical and clinical studies, molecular studies of patient samples and the design and conduct of clinical trials, which may result in important advances in the science of cancer care. The agreement also allows Dana-Farber scientists to conduct independent studies on select Lilly compounds. Following research conducted at Dana-Farber, the evaluated compounds will still be fully owned by Lilly. Financial terms of the agreement are not being disclosed.
Massachusetts Life Sciences Center and Dana-Farber Cancer Institute Announce Official Opening of Dana-Farber's Molecular Cancer Imaging Facility
Jun 8 15
Dana-Farber Cancer Institute and the Massachusetts Life Sciences Center (MLSC) celebrated the official opening of Dana-Farber's Molecular Cancer Imaging Facility in Boston's Innovation District. The laboratory focuses on making chemical tracers that 'light up' cancer cells and molecular pathways, a technology for research on improving cancer diagnosis and developing precision drugs matched to individual patients. The Molecular Cancer Imaging Facility (MCIF) includes a cyclotron for making short-lived molecular imaging probes that are tracked by PET scanners. The process is key to evaluating experimental drugs and showing whether they hit vulnerable targets within cancer cells. Construction of the facility at Dana-Farber's Harbor Campus in South Boston's Innovation District was made possible through a $10 million grant from the MLSC, a state-funded investment agency that supports life sciences innovation, research, development and commercialization. The MLSC is charged with implementing the state's 10-year, $1 billion Life Sciences Initiative.
Dana-Farber Cancer Institute, Inc. Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015
May 17 15
Dana-Farber Cancer Institute, Inc. Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015. Venue: Hyatt Chicago Magnificent Mile, Chicago, Illinois, United States. Presentation Date & Speakers: May-29-2015, O. Prem Das, Chief Research Business Development Officer.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|